Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-15-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-6-years-of-age/
https://www.globenewswire.com/en/news-release/2024/07/09/2910781/0/en/FDA-Approves-Arcutis-ZORYVE-roflumilast-Cream-0-15-for-the-Treatment-of-Atopic-Dermatitis-in-Adults-and-Children-Down-to-6-Years-of-Age.html
https://www.globenewswire.com/en/news-release/2024/07/09/2910308/0/en/Arcutis-Provides-Update-on-sNDA-for-Roflumilast-Cream-0-15-for-Atopic-Dermatitis.html
https://www.globenewswire.com/news-release/2024/07/03/2908424/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/10/2896346/0/en/Arcutis-Announces-New-Long-Term-Data-of-Roflumilast-Cream-0-15-for-the-Treatment-of-Mild-to-Moderate-Atopic-Dermatitis-AD-in-Adults-and-Children-Down-to-Age-Six-Presented-at-Revolu.html
https://www.globenewswire.com/news-release/2024/06/05/2893821/0/en/Arcutis-Announces-Multiple-Abstracts-Including-Oral-Presentation-Accepted-at-the-Revolutionizing-Alopecia-Areata-Vitiligo-and-Eczema-Conference.html
https://www.globenewswire.com/news-release/2024/06/05/2894259/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/03/2892203/0/en/Arcutis-to-Present-at-the-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/14/2881825/0/en/Arcutis-Announces-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/13/2880376/0/en/Expert-Panel-Review-Further-Validates-Use-of-ZORYVE-roflumilast-Topical-Foam-0-3-for-Treatment-of-Seborrheic-Dermatitis-Across-Diverse-Hair-Types-Published-in-Journal-of-Clinical-a.html